Jefferies Financial Group Trims Regeneron Pharmaceuticals (REGN) Target Price to $343.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by Jefferies Financial Group from $376.00 to $343.00 in a research note issued on Wednesday, The Fly reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price indicates a potential downside of 6.71% from the company’s previous close.

Other equities research analysts have also issued research reports about the company. TheStreet raised Regeneron Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, January 17th. Guggenheim raised Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $461.00 price target on the stock in a research note on Friday, January 4th. Zacks Investment Research raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $472.00 price target on the stock in a research note on Thursday, February 7th. BidaskClub lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 7th. Finally, Cowen reissued a “hold” rating and set a $385.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, January 7th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $413.94.

Shares of REGN opened at $367.69 on Wednesday. Regeneron Pharmaceuticals has a twelve month low of $281.89 and a twelve month high of $442.00. The company has a market capitalization of $40.18 billion, a price-to-earnings ratio of 18.57, a price-to-earnings-growth ratio of 1.46 and a beta of 1.18. The company has a debt-to-equity ratio of 0.08, a quick ratio of 3.67 and a current ratio of 4.47.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, February 6th. The biopharmaceutical company reported $6.84 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $5.10 by $1.74. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.73 billion. Regeneron Pharmaceuticals had a return on equity of 29.77% and a net margin of 36.43%. The company’s quarterly revenue was up 21.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.23 EPS. Analysts expect that Regeneron Pharmaceuticals will post 19.92 EPS for the current year.

In related news, major shareholder Sanofi sold 131,115 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $412.17, for a total transaction of $54,041,669.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 12.42% of the company’s stock.

Several institutional investors have recently modified their holdings of the stock. Joel Isaacson & Co. LLC raised its position in shares of Regeneron Pharmaceuticals by 0.8% during the 1st quarter. Joel Isaacson & Co. LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $1,249,000 after purchasing an additional 25 shares during the last quarter. Diversified Trust Co raised its holdings in Regeneron Pharmaceuticals by 0.8% in the 4th quarter. Diversified Trust Co now owns 3,630 shares of the biopharmaceutical company’s stock valued at $1,356,000 after acquiring an additional 30 shares during the last quarter. Comprehensive Portfolio Management LLC raised its holdings in Regeneron Pharmaceuticals by 4.1% in the 1st quarter. Comprehensive Portfolio Management LLC now owns 833 shares of the biopharmaceutical company’s stock valued at $342,000 after acquiring an additional 33 shares during the last quarter. Kaizen Advisory LLC raised its holdings in Regeneron Pharmaceuticals by 21.2% in the 4th quarter. Kaizen Advisory LLC now owns 200 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 35 shares during the last quarter. Finally, Whittier Trust Co. raised its holdings in Regeneron Pharmaceuticals by 195.7% in the 4th quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 66.97% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: How can you know how many shares are floating?

The Fly

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.